Oxycodone Market Size And Trend Analysis By Application, By Region And Segment Forecast 2019 – 2026

The oxycodone market is driven by an increase in the number of patients suffering from terminally ill diseases.

Market Size – USD 4.68 Billion in 2018, Market Growth - CAGR of 4.6%, Market Trends – Expanding occurrence of diseases that cause chronic pain, such as postsurgical pain, back pain, cancer and fibromyalgia is boosting the market.

The Oxycodone Market is estimated to grow from USD 4.68 Billion in 2018 to USD 6.78 Billion by 2026, at a CAGR of 4.6%, during the forecast period. The oxycodone market is driven by an increase in the number of patients suffering from terminally ill diseases such as cancer and HIV and a high increase in the prescription of post-operative pain medication.

Cancer's growing commonness, Parkinson's disease, and rheumatic diseases drive the growth of the market. The use of oxycodone to relieve post-operative pain under different medical conditions fuels the growth of the market.

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/press-release/global-oxycodone-market 

Further key findings from the report suggest

• The Oxycodone Market is estimated to grow from USD 4.68 Billion in 2018 to USD 6.78 Billion by 2026, at a CAGR of 4.6%, during the forecast period. The oxycodone market is driven by an increase in the number of patients suffering from terminally ill diseases such as cancer and HIV and a high increase in the prescription of post-operative pain medication.
• The market for short acting oxycodone is expected to hold the largest market share at USD 5.09 Billion by 2026, at a CAGR of 5.5% during the forecast period. An increase in pharmaceutical companies new drug applications and the number of products in the pipeline are driving the market for oxycodone. Other formulations are coming up on the market, such as controlling the release of drugs to improve pain management.
• Based on routes of administration, the oral segment is expected to hold the largest market share and is expected to reach USD 2.98 Billion by 2026, at a CAGR of 5.8% during the forecast period. Oxycodone is only approved for mouth use in the United States, which is available as tablets and oral solutions. However, oxycodone parenteral formulations (brand name OxyNorm) are also available worldwide and are widely used in Europe.
• The major players in the market are Johnson & Johnson (US), Sanofi (France), Pfizer (US), Purdue Pharma (US), Endo International (Ireland), Teva Pharmaceuticals (Israel), Hikma Pharmaceuticals (UK), Mallinckrodt (UK), Mylan (US), Sun Pharmaceutical (India), Impax Laboratories (US), Indivior (UK) and others.

Segments covered in the report:

This report forecasts volume and revenue growth at a global, regional & country level, and provides an analysis on the industry trends in each of the sub-segments from 2016 to 2026. For the purpose of this study, Reports and Data have segmented the market on the basis of type, routes of administration, application, distribution channel and regional analysis.

Type (Kilo Tons) (Revenue, USD Million; 2016-2026)

• Short Acting Oxycodone
• Long Acting Oxycodone

Routes of Administration (Kilo Tons) (Revenue, USD Million; 2016-2026)

• Oral
• Sublingual
• Intramuscular
• Intravenous
• Intranasal
• Subcutaneous
• Transdermal
• Rectal
• Epidural

Distribution (Kilo Tons) (Revenue, USD Million; 2016-2026)

• Hospital Pharmacies
• Retail Pharmacies
• Others

Application (Kilo Tons) (Revenue, USD Million; 2016-2026)

• De-Addiction
• Pain Management

Region (Kilo Tons) (Revenue, USD Million; 2016-2026)

• North America
  • U.S
• Europe
  • France
  • UK
• Asia Pacific
  • China
  • India
  • Japan
• Latin America
  • Brazil

Request For Free PDF Sample Of This Research Report At: https://www.reportsanddata.com/sample-enquiry-form/1286